Maria Letizia Cataldo

FOXA1 upregulation promotes enhancer and transcriptional reprogramming in endocrine-resistant breast cancer

Xiaoyong Fu, Resel Pereira, Carmine De Angelis et al. · Proceedings of the National Academy of Sciences · 2019 · 171 citations · Full text

Medicine, Genetics, Oncology +17

Activation of the IFN Signaling Pathway is Associated with Resistance to CDK4/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast Cancer

Carmine De Angelis, Xiaoyong Fu, Maria Letizia Cataldo et al. · Clinical Cancer Research · 2021 · 94 citations · Full text

Medicine, Oncology, Pharmacology +17

Evaluation of the Predictive Role of Tumor Immune Infiltrate in Patients with HER2-Positive Breast Cancer Treated with Neoadjuvant Anti-HER2 Therapy without Chemotherapy

Carmine De Angelis, Chandandeep Nagi, Cliff C. Hoyt et al. · Clinical Cancer Research · 2019 · 87 citations · Full text

Medicine, Immunology, Oncology +17

The oral selective oestrogen receptor degrader (SERD) AZD9496 is comparable to fulvestrant in antagonising ER and circumventing endocrine resistance

Agostina Nardone, Hazel M. Weir, Oona Delpuech et al. · British Journal of Cancer · 2018 · 65 citations · Full text

Medicine, Oncology, Pharmacology +15

NPY1R exerts inhibitory action on estradiol-stimulated growth and predicts endocrine sensitivity and better survival in ER-positive breast cancer

Raksha R. Bhat, Hariprasad Thangavel, Noor Mazin Abdulkareem et al. · Scientific Reports · 2022 · 27 citations · Full text

Life Sciences, Endocrinology, Oncology +17